Measles

1. Clinical Overview

Measles (rubeola) is a highly contagious viral infection caused by the measles virus, a paramyxovirus. It is characterized by the classic triad of cough, coryza, and conjunctivitis (the "3 Cs"), followed by a characteristic maculopapular rash. Koplik spots on the buccal mucosa are pathognomonic. Despite effective vaccination, measles remains a leading cause of vaccine-preventable deaths worldwide, particularly in children under 5 years in resource-limited settings. Complications include pneumonia, encephalitis, and subacute sclerosing panencephalitis (SSPE), a rare but fatal late complication.

Clinical Pearls:

• One of the most contagious diseases known (R0 = 12-18)
• Koplik spots appear 1-2 days before rash, pathognomonic
• Rash starts behind ears, spreads cephalocaudally
• Vitamin A supplementation reduces mortality by 50% in malnourished children
• MMR vaccine is 97% effective with 2 doses

Red Flags:

• Pneumonia: Most common cause of death, especially in malnourished children
• Encephalitis: 1 in 1000 cases, high mortality and morbidity
• Severe dehydration: From high fever and poor oral intake
• Subacute sclerosing panencephalitis: Late complication, 7-10 years post-infection, fatal
• Immunocompromised: More severe disease, higher complication rates

2. Epidemiology

Measles was historically a universal childhood infection. Vaccination has dramatically reduced incidence, but outbreaks continue due to vaccine hesitancy and gaps in coverage.

Key Statistics:

• Global incidence: 9.8 million cases in 2022 (WHO)
• Mortality: 136,000 deaths in 2022, mostly children under 5
• Pre-vaccine era: 2-3 million deaths annually
• Vaccine coverage: 83% globally with first dose (2022)
• Outbreaks: Continue in areas with less than 95% vaccination coverage

Geographic Distribution:

• Endemic: Many African and Asian countries
• Eliminated: Americas (2016), but outbreaks occur
• Resurgence: Europe, USA due to vaccine hesitancy
• High-risk areas: Low vaccination coverage regions

Age Distribution:

• Peak: 1-4 years in unvaccinated populations
• Shift: Older age groups in vaccinated populations (outbreaks)
• Infants: less than 12 months at risk if mother unvaccinated
• Adults: More severe disease, higher complication rates

Risk Factors:

• Unvaccinated: Primary risk factor
• Malnutrition: Increases severity and mortality
• Vitamin A deficiency: Increases risk of complications
• Immunocompromised: More severe disease
• Crowded conditions: Facilitates transmission

Mortality and Morbidity:

• Case fatality: 0.1-0.2% in developed countries, 1-5% in developing
• Complications: 30% of cases have complications
• Long-term: SSPE in 1 in 10,000-25,000 cases
• Disability: Blindness, hearing loss, neurological sequelae

3. Pathophysiology

Measles virus infection follows a characteristic pattern of viral replication, immune response, and tissue damage. Understanding pathophysiology explains clinical features and complications.

Viral Characteristics

Measles Virus (MeV):

• Classification: Genus Morbillivirus, family Paramyxoviridae [1]
• Structure: Single-stranded negative-sense RNA virus, enveloped
• Size: 120-250 nm diameter
• Genome: Approximately 16,000 nucleotides encoding 8 proteins
• Antigenicity: Single serotype (no antigenic variation)
• Stability: Labile in environment, inactivated by heat, UV light, pH extremes

Viral Proteins:

• Hemagglutinin (H): Binds to host cell receptors CD150 (SLAM) and nectin-4
• Fusion (F) protein: Facilitates viral envelope fusion with host cell membrane
• Matrix (M) protein: Structural protein, coordinates viral assembly
• Nucleoprotein (N): Encapsidates viral RNA genome
• Polymerase complex (L, P): Viral replication machinery
• C and V proteins: Interfere with innate immune responses

Molecular Pathogenesis

Stage 1: Viral Entry and Initial Infection (Days 0-2)

Transmission:

• Route: Respiratory droplets and aerosols from infected individuals
• Viral load: High in respiratory secretions during prodrome and early rash
• Infectivity: R0 of 12-18, making measles one of the most contagious diseases [2]
• Environmental persistence: Virus remains infectious in air for up to 2 hours

Primary Infection:

1. Virus enters respiratory tract, initially infecting respiratory epithelial cells
2. MeV hemagglutinin binds to nectin-4 on epithelial cells of the airways
3. Fusion protein mediates entry into cells
4. Virus begins replication in respiratory epithelium and conjunctival mucosa

Stage 2: Primary Viremia (Days 2-4)

Lymphatic Spread:

• Infected epithelial cells release virus to draining lymph nodes
• Virus infects dendritic cells and alveolar macrophages in respiratory tract
• CD150 (SLAM) receptor on immune cells becomes primary viral target
• SLAM expressed on activated lymphocytes, dendritic cells, macrophages

Immune Cell Infection:

• MeV shows tropism for immune cells expressing CD150
• Virus replicates in lymphoid tissues (tonsils, adenoids, Peyer's patches)
• Formation of multinucleated giant cells (Warthin-Finkeldey cells) in lymphoid tissue
• Primary viremia: Infected immune cells seed virus throughout lymphoid system

Stage 3: Secondary Viremia and Dissemination (Days 5-11)

Systemic Spread:

• Infected lymphocytes and monocytes disseminate virus via bloodstream
• Virus reaches multiple organ systems:
  • "Skin: Infection of dermal endothelial cells"
  • "Lungs: Infection of respiratory epithelium and endothelium"
  • "Gastrointestinal tract: Mucosal infection"
  • "Liver, spleen: Reticuloendothelial involvement"
  • "Central nervous system: Potential CNS seeding"
• Peak viral replication occurs during this phase

Stage 4: Prodromal Phase (Days 10-14)

Immune Response Activation:

• Development of measles-specific T-cell responses
• Production of pro-inflammatory cytokines (IFN-γ, IL-2, TNF-α)
• Cytokine-mediated symptoms: fever, malaise, anorexia
• Respiratory symptoms from viral-induced inflammation

Koplik Spots Pathogenesis:

• Formation: Days 11-12 post-infection
• Mechanism: Focal necrosis of oral epithelium with viral replication
• Location: Buccal mucosa opposite second molars
• Appearance: White papules on erythematous base
• Timing: Appear 1-2 days before rash, disappear as rash emerges
• Pathognomonic significance: Specific to measles virus infection

Stage 5: Exanthem Phase (Days 14-18)

Rash Development Mechanisms:

• Cellular Basis: T-cell-mediated immune response against infected endothelial cells
• Immune Complex Deposition: Antibody-antigen complexes in dermal vessels
• Endothelial Damage: Infection of vascular endothelium causing inflammation
• Cytokine Release: IL-1, TNF-α, IL-6 contributing to vascular changes

Rash Characteristics:

• Onset: 14 days post-infection (coincides with antibody development)
• Initial location: Hairline, behind ears, upper neck
• Progression: Cephalocaudal spread over 3-4 days
• Mechanism of spread: Sequential immune-mediated clearance
• Evolution: Maculopapular → confluent → desquamation
• Duration: 5-7 days, fades in order of appearance

Stage 6: Measles-Induced Immunosuppression

Mechanisms of Immune Suppression:

• Lymphopenia: Depletion of T and B lymphocytes through apoptosis [3]
• Dendritic Cell Dysfunction: Impaired antigen presentation
• IL-10 Production: Immunosuppressive cytokine upregulation
• Thymic Atrophy: Temporary involution of thymus
• Decreased Cellular Immunity: Reduced delayed-type hypersensitivity
• B-cell Suppression: Impaired antibody responses to other antigens

Clinical Consequences:

• Duration: Immunosuppression lasts 2-3 months post-infection [4]
• Increased susceptibility: Secondary bacterial infections (pneumonia, otitis media)
• Reactivation risk: Potential reactivation of latent infections (tuberculosis)
• Vaccine responses: Reduced responses to concurrent vaccinations
• Immune memory: "Immune amnesia"
• loss of pre-existing immune memory to other pathogens

Stage 7: Complication Pathogenesis

Pneumonia:

• Direct viral pneumonitis: MeV infection of respiratory epithelium and endothelium
• Giant cell pneumonia: Multinucleated giant cells in alveoli (immunocompromised)
• Secondary bacterial: Immunosuppression allows bacterial superinfection
• Pathology: Diffuse alveolar damage, hyaline membranes, interstitial infiltrates

Acute Measles Encephalitis:

• Incidence: 1 in 1,000 cases [5]
• Timing: 2-6 days after rash onset
• Mechanism: Post-infectious demyelination (immune-mediated, not direct viral invasion)
• Pathology: Perivenular demyelination, lymphocytic infiltration
• Presentation: Altered consciousness, seizures, focal neurological deficits

Subacute Sclerosing Panencephalitis (SSPE):

• Incidence: 4-11 per 100,000 measles cases [6]
• Latency: 7-10 years post-infection (mean 7 years)
• Risk factors: Measles infection before age 2 years
• Mechanism: Persistent CNS infection with defective measles virus
  • Mutations in M and F proteins prevent viral assembly and release
  • Virus spreads cell-to-cell without budding
  • Progressive neuronal loss and gliosis
• Pathology: Widespread neuronal degeneration, gliosis, inclusion bodies
• Outcome: Invariably fatal within 1-3 years of symptom onset

Stage 8: Recovery and Long-term Immunity

Immune Resolution:

• Development of measles-specific neutralizing antibodies (IgG)
• Peak antibody titers at 2-4 weeks post-rash
• Establishment of immunological memory
• Recovery of cellular immunity over 2-3 months

Lifelong Immunity:

• Natural infection confers lifelong immunity in > 99% of cases
• Both humoral and cellular immunity maintained
• Memory B and T cells persist for life
• Reinfection extremely rare and typically asymptomatic

4. Risk Factors

Non-Modifiable Risk Factors:

• Age: Infants less than 12 months (maternal antibodies wane, too young for vaccine)
• Immunocompromised: HIV, chemotherapy, immunosuppressive medications
• Malnutrition: Protein-energy malnutrition, micronutrient deficiencies
• Pregnancy: Increased severity, risk to fetus

Modifiable Risk Factors:

• Unvaccinated: Primary preventable risk factor
• Vitamin A deficiency: Increases complication risk
• Malnutrition: Worsens outcomes
• Crowded living: Facilitates transmission
• Travel: To endemic areas without immunity

High-Risk Groups:

• Unvaccinated children: Highest risk
• Infants: Too young for vaccination, rely on herd immunity
• Immunocompromised: More severe disease, may not mount adequate immune response to vaccine
• Healthcare workers: Occupational exposure risk
• Travelers: To endemic areas

Protective Factors:

• Vaccination: 97% effective with 2 doses of MMR
• Prior infection: Lifelong immunity (rare reinfection)
• Maternal antibodies: Protect infants less than 6 months
• Herd immunity: 95% vaccination coverage prevents outbreaks

5. Clinical Presentation

Measles follows a characteristic clinical course: incubation, prodrome, rash, and recovery. Recognition of the classic features enables early diagnosis and isolation.

Incubation Period:

• Duration: 10-14 days (range 7-21 days)
• Asymptomatic: No symptoms during this period
• Contagious: Not yet contagious

Prodromal Phase (2-4 days):

• Fever: High-grade (39-40°C), persistent
• The "3 Cs":
  • "Cough: Dry, persistent"
  • "Coryza: Profuse nasal discharge"
  • "Conjunctivitis: Red, watery eyes, photophobia"
• Koplik spots: White spots on buccal mucosa, pathognomonic, appear 1-2 days before rash
• Malaise: Severe fatigue, irritability
• Anorexia: Poor appetite

Exanthem Phase:

• Rash onset: 3-5 days after prodrome starts
• Appearance: Maculopapular, erythematous
• Distribution: Starts behind ears, spreads cephalocaudally (head → trunk → extremities)
• Evolution: Discrete spots → confluent → desquamation
• Duration: 5-7 days, fades in order of appearance
• Fever: Persists during rash phase, resolves as rash fades

Koplik Spots:

• Location: Buccal mucosa, opposite second molars
• Appearance: Tiny white spots on erythematous background
• Timing: 1-2 days before rash, disappear as rash appears
• Significance: Pathognomonic for measles

Recovery Phase:

• Duration: 1-2 weeks
• Desquamation: Fine desquamation as rash fades
• Convalescence: Gradual return of energy and appetite
• Immunity: Lifelong after natural infection

Atypical Presentations:

• Modified measles: Milder in partially immune (vaccinated or maternal antibodies)
• Atypical measles: In recipients of killed vaccine (historical)
• Hemorrhagic measles: Rare, severe form with bleeding
• Immunocompromised: More severe, prolonged, may lack rash

6. Examination

Clinical diagnosis is usually straightforward based on characteristic features. Examination focuses on identifying diagnostic signs and assessing for complications.

General Examination:

• Vital signs: High fever (39-40°C), tachycardia
• Appearance: Ill-appearing, miserable child
• Dehydration: Assess for signs (dry mucosa, reduced urine output)

Head and Neck:

• Koplik spots: Buccal mucosa, opposite molars (pathognomonic)
• Conjunctivitis: Bilateral, red, watery, photophobia
• Coryza: Profuse nasal discharge
• Pharyngitis: Red throat, may be present

Respiratory:

• Cough: Dry, persistent, may be severe
• Respiratory distress: Tachypnea, retractions (pneumonia)
• Auscultation: Wheeze, crepitations (pneumonia)
• Oxygen saturation: Check if respiratory symptoms

Dermatological:

• Rash: Maculopapular, starts behind ears
• Distribution: Cephalocaudal spread
• Character: Discrete → confluent
• Desquamation: Fine scaling as rash fades

Neurological:

• Meningeal signs: If encephalitis suspected
• Focal deficits: Rare, suggests encephalitis
• Seizures: May occur with encephalitis

Complications Assessment:

• Pneumonia: Respiratory distress, crepitations
• Otitis media: Ear pain, bulging tympanic membrane
• Encephalitis: Altered mental status, seizures
• Dehydration: Clinical signs, assess severity

7. Investigations

Diagnosis is usually clinical. Laboratory confirmation is important for public health surveillance, atypical cases, and outbreak investigation.

Clinical Diagnosis Criteria

WHO Clinical Case Definition:

• Fever ≥38°C (101°F) PLUS
• Generalized maculopapular rash PLUS
• At least one of: cough, coryza, or conjunctivitis

Diagnostic Accuracy:

• Sensitivity: 77% (clinical diagnosis alone)
• Specificity: 95% with Koplik spots present
• Positive predictive value: Varies with outbreak setting (higher during outbreaks)

Public Health Requirements:

• Measles is a notifiable disease in most countries
• Report immediately to public health authorities
• Isolation required until 4 days after rash onset
• Contact tracing initiated for all exposed individuals

Laboratory Confirmation

Indications for Laboratory Testing:

• Public health surveillance (all suspected cases)
• Atypical presentations
• Outbreak investigation and strain typing
• Immunocompromised patients
• Vaccinated individuals with suspected measles
• Diagnosis confirmation for medicolegal purposes

Specimen Collection Timing:

• Optimal: Within 3-7 days of rash onset
• IgM: 3 days to 8 weeks post-rash
• RT-PCR: Most sensitive during prodrome and first 3 days of rash
• Viral culture: Within first week of rash

Serological Testing

IgM Antibody Detection:

• Method: Enzyme immunoassay (EIA), indirect immunofluorescence
• Timing:
  • "Detectable: 3-4 days after rash onset"
  • "Peak: 7-10 days post-rash"
  • "Duration: 1-2 months (occasionally up to 3 months)"
• Sensitivity:
  • 77% if collected 0-72 hours post-rash [7]

  • 95% if collected 4-14 days post-rash

  • Decreases after 4 weeks
• Specificity: 95-98%
• False Negatives:
  • Sample collected too early (less than 3 days post-rash)
  • Immunocompromised patients (may not mount IgM response)
  • Vaccinated individuals (may have blunted IgM response)
• False Positives:
  • Other viral infections (EBV, parvovirus B19, rubella)
  • Recent MMR vaccination (rare, usually low-level)
  • Rheumatoid factor interference

IgG Antibody Testing:

• Acute Phase IgG: Detectable 7-10 days after rash onset
• Convalescent IgG: Measured 10-14 days after acute sample
• Diagnostic Criterion: 4-fold rise in IgG titre between acute and convalescent sera
• Interpretation:
  • Low positive IgG + positive IgM = acute infection
  • High IgG alone = past infection or vaccination
  • Rising IgG (paired sera) = recent infection
• Use: Primarily for retrospective diagnosis or immunity assessment

Molecular Testing

RT-PCR (Reverse Transcription Polymerase Chain Reaction):

• Specimen Types:
  • Throat/nasopharyngeal swab (preferred)
  • Urine (high viral load, useful 1-14 days post-rash)
  • Blood (PBMC or serum)
  • Oral fluid (saliva)
  • CSF (if encephalitis suspected)
• Sensitivity:
  • 94-100% during prodrome and first 3 days of rash
  • Decreases after day 5 of rash
  • More sensitive than viral culture
• Specificity: > 99%
• Advantages:
  • Most sensitive method during early illness
  • Detects virus in vaccinated individuals (differentiates wild-type from vaccine strain)
  • Rapid turnaround (24-48 hours)
  • Allows genotyping for outbreak investigation
• Clinical Utility:
  • Confirms diagnosis when serology negative or equivocal
  • Essential in outbreak settings for strain typing
  • Useful in immunocompromised (may lack IgM response)

Genotyping:

• Purpose: Distinguishes wild-type from vaccine strain, tracks transmission chains
• Method: Sequence analysis of N gene (450 nucleotides)
• WHO Classification: 24 recognized genotypes (A-H)
• Endemic Genotypes: Vary by region (B3, D4, D8, H1 common globally)
• Vaccine Strains: Genotype A (not seen in wild)

Viral Culture

Specimens:

• Throat swab, nasopharyngeal aspirate
• Urine (best yield)
• Conjunctival swab
• Blood (buffy coat)

Culture Systems:

• Vero/SLAM cells (express CD150 receptor)
• Primary monkey kidney cells
• B95a cells (marmoset B-lymphoblastoid line)

Limitations:

• Time-consuming: 5-10 days for cytopathic effect
• Requires specialized laboratory facilities
• Lower sensitivity than RT-PCR
• Rarely used clinically (mainly for research and strain characterization)

Additional Laboratory Investigations

Complete Blood Count:

• Leucopenia: Common (WBC 3,000-5,000/μL)
• Lymphopenia: Absolute lymphopenia during acute phase
• Thrombocytopenia: Occasionally seen
• Atypical Lymphocytes: May be present
• Clinical Correlation: Leucopenia reflects immunosuppression

C-Reactive Protein (CRP):

• Usually mildly elevated (20-50 mg/L)
• Marked elevation suggests bacterial superinfection

Liver Function Tests:

• Transaminitis: Mild elevation common (ALT 50-200 U/L)
• Usually resolves spontaneously
• Monitor if clinical concern for hepatitis

Vitamin A Levels:

• Indication: Malnourished children, developing countries
• Significance: Deficiency increases complication risk
• Threshold: less than 20 μg/dL indicates deficiency
• Management: Guide vitamin A supplementation

Investigations for Complications

Respiratory Complications:

Chest Radiography:

• Indications:
  • Respiratory distress, hypoxemia
  • Persistent fever beyond typical course
  • Clinical signs of pneumonia
• Findings:
  • "Viral pneumonitis: Bilateral reticulonodular infiltrates, perihilar distribution"
  • "Bacterial superinfection: Lobar consolidation, pleural effusion"
  • "Giant cell pneumonia: Diffuse bilateral infiltrates (immunocompromised)"
• Complications: Pneumatoceles, pneumothorax (rare)

Pulse Oximetry:

• Continuous monitoring if respiratory symptoms
• Threshold for oxygen: SpO2 less than 92% (room air)

Arterial Blood Gas:

• If severe respiratory distress or altered consciousness
• Assess for respiratory failure, metabolic acidosis

Neurological Complications:

Lumbar Puncture (if encephalitis suspected):

• Indications:
  • Altered mental status, seizures
  • Focal neurological signs
  • Severe headache, meningism
• CSF Findings in Acute Measles Encephalitis:
  • "Pleocytosis: 10-200 cells/μL (lymphocyte predominant)"
  • "Protein: Mildly elevated (0.5-1.5 g/L)"
  • "Glucose: Normal"
  • "Measles IgM/IgG: May be detectable"
  • "PCR: Usually negative (post-infectious, not direct invasion)"
• CSF in SSPE:
  • Elevated protein
  • Elevated IgG with oligoclonal bands
  • Measles antibodies in CSF
  • PCR may detect measles RNA

Electroencephalography (EEG):

• Acute Encephalitis: Diffuse slowing, epileptiform activity
• SSPE: Periodic complexes (high-amplitude slow waves every 4-15 seconds)

Neuroimaging (MRI Brain):

• Acute Encephalitis:
  • T2/FLAIR hyperintensities in white matter (demyelination)
  • Usually bilateral and symmetric
• SSPE:
  • Progressive white matter changes
  • Cortical atrophy
  • Basal ganglia involvement

Differential Diagnosis Investigations

When Diagnosis Uncertain:

Monitoring Investigations

During Acute Illness:

• Daily clinical assessment
• Vital signs including temperature, oxygen saturation
• Hydration status (urine output, mucous membranes)
• Respiratory examination (pneumonia screening)

Follow-up:

• Hearing assessment: If otitis media or encephalitis
• Developmental assessment: If neurological complications
• Vitamin A: Repeat level if supplemented

Differential Diagnosis Considerations:

8. Management

Management is primarily supportive as there is no specific antiviral therapy for measles. Vitamin A supplementation reduces mortality by up to 50% in high-risk populations. [8] Complications require specific treatment. Public health measures including isolation and contact tracing are essential.

MEASLES MANAGEMENT ALGORITHM
============================

Suspected Measles Case
        |
        v
Clinical Assessment
- Fever + rash + cough/coryza/conjunctivitis
- Look for Koplik spots
- Assess severity and complications
        |
        +-----------------+-----------------+
        |                                   |
    IMMEDIATE ACTIONS              LABORATORY CONFIRMATION
        |                                   |
    - Isolate (airborne precautions)   - IgM serology
    - Notify public health             - RT-PCR (throat swab, urine)
    - Contact tracing                  - Viral culture if available
    - Assess vaccination status        - Genotyping (outbreaks)
        |
        v
SUPPORTIVE CARE
===============
- Isolation until 4 days post-rash
- Rest, adequate hydration
- Antipyretics (paracetamol/ibuprofen)
- Nutritional support
- Monitor for complications
        |
        v
VITAMIN A SUPPLEMENTATION (ALL CASES)
=====================================
Age-based dosing:
- less than 6 months: 50,000 IU PO
- 6-11 months: 100,000 IU PO
- ≥12 months: 200,000 IU PO

Timing: Give 2 doses
- Day 1 of diagnosis
- Day 2 (next day)
- Additional dose at 4 weeks if:
  * Clinical vitamin A deficiency
  * Severe malnutrition
  * Ophthalmological complications

        |
        v
COMPLICATION ASSESSMENT
=======================
        |
        +--------+--------+--------+--------+
        |        |        |        |        |
    Pneumonia Encephalitis Dehydration Otitis Other
        |        |        |        |        |
        v        v        v        v        v
COMPLICATION MANAGEMENT
=======================

PNEUMONIA:
----------
• Assess severity (respiratory rate, oxygen saturation, work of breathing)
• Oxygen if SpO2 less than 92%
• Antibiotics for bacterial superinfection:
  - "First-line: Amoxicillin 40-50 mg/kg/dose TDS PO"
  - "Severe: Ceftriaxone 50-75 mg/kg IV OD"
  - Consider co-amoxiclav if no response
• CXR to confirm diagnosis
• Monitor closely, admit if severe
• Supportive care: IV fluids if needed

ENCEPHALITIS:
-------------
• Admit to intensive care
• Supportive care: Airway, breathing, circulation
• Seizure management:
  - Benzodiazepines (lorazepam 0.1 mg/kg IV)
  - "Second-line: Phenytoin, levetiracetam"
• ICP management if elevated:
  - Head elevation, avoid hypoxia/hypercapnia
  - Consider mannitol if signs of herniation
• Lumbar puncture if safe (exclude raised ICP)
• Consider HSV co-infection: Acyclovir 10 mg/kg TDS IV
• Neuroimaging: MRI brain
• Long-term follow-up for sequelae

DEHYDRATION:
-----------
• Assess severity (mild/moderate/severe)
• Mild-moderate: ORS 75 mL/kg over 4 hours
• Severe: IV fluids
  - 0.9% saline or Ringer's lactate
  - 20 mL/kg bolus, repeat if needed
  - "Maintenance: Age-appropriate fluid calculation"
• Monitor: Urine output, vital signs
• Correct electrolyte abnormalities

OTITIS MEDIA:
-------------
• Amoxicillin 40-50 mg/kg/day divided TDS for 5-7 days
• Analgesia: Paracetamol or ibuprofen
• Follow-up: Ensure resolution
• Hearing assessment if persistent

LARYNGOTRACHEOBRONCHITIS:
------------------------
• Assess airway: Stridor, respiratory distress
• Dexamethasone 0.15-0.6 mg/kg PO/IM (single dose)
• Nebulized adrenaline if severe
• Oxygen if hypoxemic
• Admit if severe or concerning

VITAMIN A DEFICIENCY COMPLICATIONS:
-----------------------------------
• Ophthalmology referral if corneal involvement
• Additional vitamin A doses
• Antibiotic eye drops if secondary infection
• Protect eyes: Eye shield, dark room

        |
        v
POST-EXPOSURE PROPHYLAXIS (Contacts)
====================================
Assess exposure and immunity status of contacts:

UNVACCINATED/INCOMPLETELY VACCINATED:
- Age ≥12 months: MMR within 72 hours of exposure
- Likely 90% protective if given promptly

CONTRAINDICATION TO MMR (infants less than 12 months, 
immunocompromised, pregnant):
- Immunoglobulin (IMIG) within 6 days of exposure
- Dosing:
  * Immunocompetent: 0.5 mL/kg IM (max 15 mL)
  * Immunocompromised: 400 mg/kg IV (IVIG)
- Provides passive immunity, prevents/modifies disease

EXPOSURE DEFINITION:
- Household contact
- Face-to-face contact > 15 minutes
- Shared enclosed space for > 2 hours
- During infectious period (4 days before to 4 days after rash)

        |
        v
FOLLOW-UP
=========
• Monitor until resolution (typically 2 weeks)
• Assess for late complications
• Ensure completion of MMR schedule when appropriate
• Hearing screen if otitis media or encephalitis
• Developmental assessment if neurological involvement
• Report outcomes to public health

Supportive Care Principles

General Measures:

Isolation and Infection Control:

• Duration: From diagnosis until 4 days after rash onset
• Precautions: Airborne + contact precautions
  • Negative pressure room if hospitalized
  • N95 respirator for healthcare workers
  • Limit visitors to immune individuals
• Home Isolation: If mild and no complications
  • Separate room, minimize contact with others
  • Exclude from school/childcare
• Healthcare Setting: Dedicated staff, minimize exposure

Rest and Activity:

• Encourage bed rest during acute febrile phase
• Gradual return to activity as symptoms improve
• Avoid strenuous activity until full recovery
• School/childcare exclusion until 4 days post-rash

Hydration and Nutrition:

• Fluids:
  • Encourage frequent oral fluids
  • "Age-appropriate volumes: 100-150 mL/kg/day"
  • ORS if diarrhea or poor intake
  • IV fluids if unable to maintain oral intake or severe dehydration
• Nutrition:
  • Continue breastfeeding in infants
  • Small frequent meals as tolerated
  • High-calorie, nutrient-dense foods
  • Monitor weight in prolonged illness
  • Nutritional supplementation if malnourished

Fever Management:

• Antipyretics:
  • "Paracetamol: 15 mg/kg/dose every 4-6 hours PO (max 60 mg/kg/day)"
  • "Ibuprofen: 10 mg/kg/dose every 6-8 hours PO (max 40 mg/kg/day)"
  • Avoid aspirin (Reye's syndrome risk)
• Physical Measures:
  • Light clothing, room temperature environment
  • Tepid sponging if distressed
  • Avoid cold baths (causes shivering)

Symptom Relief:

• Cough: Honey (if > 12 months), warm fluids
• Conjunctivitis:
  • Clean eyes with cooled boiled water
  • Dim lighting if photophobic
  • Artificial tears for comfort
• Oral Care:
  • Soft diet, avoid acidic/spicy foods
  • Mouth rinses with water or saline
• Skin Care:
  • Keep skin clean and dry
  • Avoid scratching (trim nails)
  • Calamine lotion for pruritus

Vitamin A Supplementation

Evidence Base:

• Reduces all-cause mortality by 50% in children [8]
• Reduces pneumonia severity and mortality [9]
• Decreases risk of croup and diarrhea
• Protective against corneal damage and blindness
• WHO recommends for ALL children with measles in developing countries

Indications (WHO Recommendations):

• All children with measles in developing countries
• High-risk children in developed countries:
  • Age 6-24 months
  • Immunocompromised (HIV, chemotherapy)
  • Malnutrition or failure to thrive
  • Clinical vitamin A deficiency (night blindness, Bitot's spots)
  • Chronic malabsorption (cystic fibrosis, IBD)
  • Recent immigration from areas with high measles mortality
  • Hospitalized with complications

Dosing Schedule:

*Third dose at 4 weeks only if: clinical vitamin A deficiency, severe malnutrition, or ophthalmological complications

Administration:

• Oral route preferred (capsule or liquid)
• Can be given IM if unable to take orally
• Give with fatty food to enhance absorption
• Document doses given

Adverse Effects:

• Generally well-tolerated at recommended doses
• Nausea, vomiting (usually mild and transient)
• Headache (rare, from acute vitamin A excess)
• Bulging fontanelle in infants (benign, resolves within 24-48 hours)
• Skin peeling (mild, delayed)

Contraindications:

• None for treatment doses
• Caution in hypervitaminosis A (extremely rare)

Specific Antiviral Therapy

Ribavirin:

• Evidence: Limited data, not routinely recommended
• Potential Use:
  • Severe measles in immunocompromised patients
  • Measles pneumonitis in severely ill patients
  • Giant cell pneumonia
• Dosing: 20-35 mg/kg/day IV divided every 8 hours
• Duration: 7-10 days or until clinical improvement
• Limitations:
  • No high-quality RCT data in measles
  • Teratogenic (contraindicated in pregnancy)
  • Costly, not widely available
  • Not approved for measles in most jurisdictions

Other Antivirals:

• No proven benefit for currently available antivirals
• Acyclovir: No activity against measles virus
• Oseltamivir: No activity against measles virus

Management of Specific Complications

Detailed Pneumonia Management:

Assessment:

• Respiratory rate (tachypnea thresholds: less than 2 months > 60, 2-12 months > 50, 1-5 years > 40)
• Oxygen saturation (normal ≥95%)
• Work of breathing (subcostal/intercostal retractions, nasal flaring)
• General danger signs (inability to drink, lethargy, seizures)

Severity Classification:

• Mild: Tachypnea, normal oxygen saturation, feeding well
• Moderate: Tachypnea, mild hypoxemia (SpO2 90-92%), some respiratory distress
• Severe: Severe tachypnea, hypoxemia (SpO2 less than 90%), significant work of breathing, danger signs

Antibiotic Selection:

• Outpatient (mild):
  • Amoxicillin 40-50 mg/kg/day divided TDS for 5 days
• Inpatient (moderate-severe):
  • Ampicillin 50 mg/kg IV QDS + Gentamicin 7.5 mg/kg IV OD
  • OR Ceftriaxone 50-75 mg/kg IV OD
  • "If treatment failure: Add macrolide (azithromycin) for atypical coverage"
• Immunocompromised:
  • "Broader spectrum: Ceftriaxone + vancomycin"
  • "Consider PCP: Co-trimoxazole"
  • "Consider fungal: Consult infectious diseases"

Supportive Care:

• Oxygen: Target SpO2 ≥92% (nasal prongs, face mask, high-flow)
• Fluids: Careful balance (avoid overhydration - ARDS risk)
• Nutrition: Nasogastric feeds if unable to feed
• Chest physiotherapy: May help secretion clearance
• Monitor: Vital signs, oxygen requirement, clinical improvement

Detailed Encephalitis Management:

Initial Stabilization:

• Airway: Assess and secure if GCS ≤8
• Breathing: Oxygen to maintain SpO2 ≥94%
• Circulation: IV access, fluid resuscitation if shocked
• Disability: GCS, pupil examination, posturing

Diagnostic Workup:

• Blood: Glucose, electrolytes, cultures, measles serology
• Lumbar puncture: If safe (no raised ICP signs)
• Neuroimaging: CT/MRI brain (MRI preferred)
• EEG: If seizures or altered consciousness

Seizure Management:

• First-line: Benzodiazepines
  • Lorazepam 0.1 mg/kg IV (max 4 mg)
  • OR Diazepam 0.25-0.5 mg/kg IV/PR (max 10 mg)
• Second-line:
  • Phenytoin 20 mg/kg IV loading, then 5 mg/kg/day divided
  • OR Levetiracetam 40-60 mg/kg IV loading, then 30 mg/kg/day divided
• Status Epilepticus: ICU, intubation, midazolam/propofol infusion

ICP Management:

• Elevate head of bed 30 degrees
• Maintain normoxia, normocapnia
• Avoid hypotonic fluids
• Osmotic therapy if signs of herniation: Mannitol 0.25-0.5 g/kg IV
• Neurosurgical consultation if deteriorating

Specific Therapy:

• HSV Encephalitis: Often co-considered
  • Acyclovir 10 mg/kg IV TDS until HSV excluded
  • Measles encephalitis doesn't respond to acyclovir
• Supportive Care:
  • Normothermia, normoglycemia
  • Treat secondary infections
  • Nutritional support
  • Physiotherapy, occupational therapy

Prognosis:

• Mortality: 15-25%
• Neurological sequelae: 25-35% of survivors
• Sequelae: Cognitive impairment, motor deficits, epilepsy, behavioral changes

Special Populations

Immunocompromised Patients:

Increased Risk Groups:

• HIV infection (especially CD4 less than 200)
• Chemotherapy recipients
• Solid organ or hematopoietic stem cell transplant
• Immunosuppressive medications (biologics, high-dose corticosteroids)
• Primary immunodeficiency

Clinical Features:

• More severe disease, higher mortality
• Prolonged viral shedding (weeks)
• May lack characteristic rash
• Giant cell pneumonia common
• Higher encephalitis risk
• No lifelong immunity post-infection

Management:

• Admit to hospital (all cases)
• Isolation: Extended duration (until viral clearance documented)
• Consider ribavirin (limited evidence)
• Aggressive supportive care
• Treat complications early
• Immune globulin if unvaccinated and exposed
• Avoid MMR vaccine during severe immunosuppression

Pregnant Women:

Risks:

• Increased severity in mother
• Higher risk of pneumonia, hospitalization
• Risk of pregnancy complications:
  • Miscarriage (early pregnancy)
  • Preterm labor
  • Low birth weight
  • Congenital measles (rare)
• No congenital malformations (unlike rubella)

Management:

• Admit if moderate-severe illness or pregnancy complications
• Supportive care as per general guidelines
• Vitamin A: Generally safe in pregnancy at treatment doses
• Monitor fetal well-being
• Liaise with obstetrics team
• Post-exposure prophylaxis: IMIG if exposed (MMR contraindicated)

Neonates and Infants less than 6 Months:

Special Considerations:

• Maternal antibodies protective if mother immune
• More severe if mother non-immune
• Cannot receive MMR (too young)
• Vitamin A dose: 50,000 IU

Management:

• Low threshold for hospitalization
• Monitor closely for complications
• Continue breastfeeding (beneficial)
• Post-exposure: IMIG if exposed and mother non-immune

Malnourished Children:

Increased Risks:

• Higher mortality (up to 10%)
• More severe complications
• Prolonged illness
• Impaired immune response

Management:

• Vitamin A supplementation (critical)
• Nutritional rehabilitation
• Broad-spectrum antibiotics (higher secondary infection risk)
• Monitor for refeeding syndrome if severe malnutrition
• Treat coexistent infections (worms, malaria, etc.)
• Long-term nutritional follow-up

Prevention Strategies

Primary Prevention: Vaccination

MMR Vaccine:

• Composition: Live attenuated measles, mumps, rubella viruses
• Schedule:
  • "Dose 1: 12-15 months"
  • "Dose 2: 4-6 years (or minimum 4 weeks after dose 1)"
• Efficacy:
  • 1 dose: 93% protective [10]
  • 2 doses: 97% protective [10]
  • "Duration: Likely lifelong"
• Herd Immunity: Requires ≥95% population coverage
• Catch-up: Unvaccinated individuals of any age should receive 2 doses

Contraindications:

• Severe immunodeficiency
• Pregnancy
• Severe allergic reaction to previous dose or vaccine components
• Recent immunoglobulin (wait 3-11 months depending on dose)

Special Situations:

• HIV: Safe if CD4 > 15% (children) or > 200 (adults)
• Mild illness: NOT a contraindication
• Egg allergy: NOT a contraindication (MMR grown in chick embryo fibroblasts)

Post-Exposure Prophylaxis:

MMR Vaccine:

• Timing: Within 72 hours of exposure
• Efficacy: ~90% if given promptly
• Indication: Unvaccinated or incompletely vaccinated, age ≥12 months
• Advantage: Provides long-term immunity

Immunoglobulin:

• Timing: Within 6 days of exposure (preferably within 72 hours)
• Dosing:
  • "Normal immunoglobulin (IMIG): 0.5 mL/kg IM (max 15 mL)"
  • "Immunocompromised: IVIG 400 mg/kg IV"
• Indications:
  • Infants less than 12 months
  • Pregnant women (non-immune)
  • Immunocompromised (cannot receive MMR)
  • Contraindication to MMR
• Effect: Prevents or modifies disease, no long-term immunity

Public Health Measures:

• Immediate notification to public health authorities
• Contact tracing: Identify all susceptible contacts
• Assessment of vaccination status
• Offer post-exposure prophylaxis
• Enhanced surveillance during outbreaks
• Communication strategies to address vaccine hesitancy

9. Complications

Measles causes significant complications, particularly in malnourished children and immunocompromised individuals. Complications are the main cause of mortality.

Respiratory Complications:

Pneumonia:

• Incidence: Most common complication (5-10% of cases)
• Causes: Primary viral or secondary bacterial
• Mortality: Leading cause of death
• Risk factors: Malnutrition, young age, immunocompromised
• Management: Antibiotics for bacterial, supportive care

Laryngotracheobronchitis:

• Croup-like symptoms: Stridor, barking cough
• Management: Supportive, may need airway support

Neurological Complications:

Acute Encephalitis:

• Incidence: 1 in 1000 cases
• Onset: 2-6 days after rash
• Presentation: Fever, altered mental status, seizures
• Mortality: 15-25%
• Sequelae: 25-35% have permanent neurological damage
• Management: Supportive, anticonvulsants

Subacute Sclerosing Panencephalitis (SSPE):

• Incidence: 1 in 10,000-25,000 cases
• Onset: 7-10 years after measles (mean 7 years)
• Presentation: Progressive neurological deterioration, myoclonus, dementia
• Course: Invariably fatal, 1-3 years from onset
• Risk: Higher if measles less than 2 years of age
• No effective treatment

Other Neurological:

• Seizures: Febrile or from encephalitis
• Transverse myelitis: Rare
• Guillain-Barré syndrome: Rare association

Other Complications:

Otitis Media:

• Incidence: 5-15% of cases
• Management: Antibiotics
• Sequelae: Rare hearing loss

Diarrhea:

• Common: Especially in malnourished
• Management: Oral rehydration, nutritional support

Keratitis:

• Corneal ulceration: Can cause blindness
• Risk: Vitamin A deficiency increases risk
• Management: Vitamin A, ophthalmology referral

Malnutrition:

• Worsening: Measles causes catabolic state
• Management: Nutritional support, vitamin A

Immunosuppression:

• Transient: Lasts weeks to months
• Risk: Increased susceptibility to other infections
• Management: Supportive, monitor for secondary infections

10. Prognosis

Prognosis is generally excellent in well-nourished, immunocompetent children with access to care. Complications significantly worsen outcomes.

Uncomplicated Measles:

• Recovery: Complete in 1-2 weeks
• Mortality: less than 0.1% in developed countries
• Sequelae: Rare, usually none
• Immunity: Lifelong after natural infection

With Complications:

• Pneumonia: Mortality 5-10% if severe
• Encephalitis: Mortality 15-25%, 25-35% have sequelae
• Overall: Case fatality 0.1-0.2% in developed countries

In Resource-Limited Settings:

• Mortality: 1-5% overall
• Higher: In malnourished children (up to 10%)
• Blindness: From keratitis, vitamin A deficiency
• Long-term: Neurological sequelae from encephalitis

Factors Affecting Prognosis:

• Age: Infants and adults have higher mortality
• Immunocompetence: Immunocompromised have worse outcomes
• Access to care: Early treatment improves outcomes
• Vitamin A: Supplementation reduces mortality

11. Evidence

Major International Guidelines

World Health Organization (WHO):

• Measles Vaccines: WHO Position Paper (2017) [11]
  • Recommends 2 doses of measles-containing vaccine
  • First dose at 12 months (or 9 months in endemic areas)
  • Second dose at 15-18 months (minimum 4 weeks after first)
  • "Target: ≥95% coverage with both doses for elimination"
  • Vitamin A supplementation for all cases in developing countries

Centers for Disease Control and Prevention (CDC):

• Prevention of Measles, Rubella, CRS, and Mumps (2013) [12]
  • MMR at 12-15 months and 4-6 years
  • Post-exposure prophylaxis recommendations
  • Outbreak control strategies
  • Healthcare worker vaccination requirements

American Academy of Pediatrics (AAP):

• Red Book 2021: Measles [13]
  • Comprehensive clinical guidance
  • Isolation precautions
  • Management recommendations
  • Special populations guidance

UK Public Health England:

• Measles: The Green Book, Chapter 21
  • UK immunisation schedule
  • Outbreak management protocols
  • Post-exposure prophylaxis guidelines

Landmark Studies and Meta-Analyses

Vaccine Efficacy:

Demicheli et al. Cochrane Review (2020) [10]

• Study Type: Systematic review and meta-analysis
• Included: 138 studies, millions of participants
• Findings:
  • "MMR vaccine effectiveness: 95% (95% CI: 92-97%) after one dose"
  • "Effectiveness: 96% (95% CI: 95-97%) after two doses"
  • Safety profile excellent
  • No evidence of association with autism, inflammatory bowel disease, or other serious harms
• Conclusion: MMR vaccine highly effective and safe
• PMID: 32309885

Phadke et al. JAMA (2016) [14]

• Study Type: Systematic review
• Question: Impact of vaccine refusal on disease outbreaks
• Findings:
  • "Vaccine refusal associated with increased risk of measles (OR 22.2, 95% CI: 11.6-42.6)"
  • Clustering of unvaccinated children drives outbreaks
  • "Herd immunity threshold: 92-95% coverage"
• Implication: Importance of maintaining high vaccination coverage
• PMID: 26914028

Vitamin A Supplementation:

Huiming et al. Cochrane Review (2005) [8]

• Study Type: Systematic review of randomized controlled trials
• Included: 7 trials, 2,274 children
• Findings:
  • "Vitamin A reduces all-cause mortality: RR 0.83 (95% CI: 0.73-0.96)"
  • "Reduces mortality in children less than 2 years: RR 0.79 (95% CI: 0.63-0.98)"
  • "Reduces pneumonia-specific mortality: RR 0.57 (95% CI: 0.24-1.37)"
  • "Reduces incidence of croup: RR 0.47 (95% CI: 0.33-0.67)"
• Conclusion: Vitamin A supplementation should be given to all children with measles
• PMID: 16235283

Imdad et al. BMJ Open (2017) [9]

• Study Type: Meta-analysis
• Findings:
  • Vitamin A reduces incidence of pneumonia-specific mortality by 61%
  • Greater benefit in vitamin A deficient populations
  • Two-dose regimen optimal
• Recommendation: Universal vitamin A supplementation for measles
• PMID: 28404617

Measles Complications:

Moss WJ. Lancet (2017) [1]

• Study Type: Comprehensive review
• Key Points:
  • Measles remains major cause of childhood mortality globally
  • Complications occur in ~30% of cases
  • Pneumonia most common cause of death
  • Immunosuppression lasts 2-3 months post-infection
  • "SSPE incidence: 4-11 per 100,000 cases"
• Clinical Relevance: Underscores importance of prevention
• PMID: 28673424

Perry RT, Halsey NA. J Infect Dis (2004) [5]

• Study Type: Comprehensive review of measles complications
• Findings:
  • "Case fatality rate: 0.1-0.3% (developed countries), 1-15% (developing)"
  • "Pneumonia: 1-6% of cases in developed countries, up to 20% in developing"
  • "Encephalitis: 1 per 1,000 cases"
  • "SSPE: 1 per 10,000 cases (higher if infection less than 2 years age)"
• Risk Factors: Malnutrition, vitamin A deficiency, young age, immunosuppression
• PMID: 15106083

Immunosuppression:

Mina et al. Science (2015) [4]

• Study Type: Population-level analysis
• Methodology: Analyzed infectious disease mortality in high-income countries pre/post measles vaccination
• Findings:
  • Measles virus causes "immune amnesia"
  • Immunosuppression lasts 2-3 years
  • Explains 50% of childhood infectious disease mortality pre-vaccine era
  • Vaccination protects against measles and secondary infections
• Paradigm Shift: Measles has broader impact on child mortality than previously recognized
• PMID: 25954009

Griffin DE. Science (2019) [3]

• Study Type: Immunological study
• Findings:
  • Measles virus depletes B and T cell memory populations
  • Loss of 11-73% of antibody repertoire
  • Recovery of lymphocyte populations takes 2-3 months
  • Explains increased susceptibility to secondary infections
• Mechanism: Direct infection and destruction of memory lymphocytes
• PMID: 31604244

Subacute Sclerosing Panencephalitis:

Wendorf et al. MMWR (2017) [6]

• Study Type: Population-based incidence study
• Setting: California, 1998-2016
• Findings:
  • "SSPE incidence: 1 in 1,387 for children with measles less than 5 years"
  • "Higher than previously estimated (older estimates: 1 in 10,000-25,000)"
  • "Risk highest if measles acquired less than 12 months: 1 in 609"
  • "Median latency: 7 years (range 1-19 years)"
• Implication: Measles in infancy carries very high SSPE risk
• PMID: 27832054

Bellini et al. Clin Microbiol Rev (2005) [15]

• Focus: SSPE pathogenesis and diagnosis
• Key Points:
  • Defective measles virus persists in CNS
  • Mutations in M and F genes prevent viral budding
  • Oligoclonal IgG bands in CSF diagnostic
  • EEG shows characteristic periodic complexes
  • No effective treatment; universally fatal
• PMID: 16223952

Measles Pathogenesis:

de Vries et al. Curr Opin Virol (2012) [2]

• Study Type: Review of measles virus biology
• Key Findings:
  • CD150 (SLAM) primary receptor on immune cells
  • Nectin-4 on epithelial cells for shedding
  • Sequential receptor use explains clinical course
  • Viral proteins inhibit innate immune responses
• Clinical Relevance: Understanding tropism explains disease manifestations
• PMID: 22749491

Laksono et al. Viruses (2016) [16]

• Focus: Measles virus host cell tropism
• Findings:
  • "Two-receptor model: CD150 for systemic spread, nectin-4 for respiratory shedding"
  • Multinucleated giant cells from cell-cell fusion
  • Immune cell infection causes immunosuppression
• PMID: 27754341

Post-Exposure Prophylaxis:

Young et al. Pediatrics (2020) [17]

• Study Type: Systematic review
• Question: Effectiveness of post-exposure prophylaxis
• Findings:
  • "MMR within 72 hours: 83-93% effective"
  • "Immunoglobulin within 6 days: 83% effective"
  • Earlier administration more effective
• Recommendation: Prompt PEP for exposed susceptible individuals
• PMID: 32047045

Recent Epidemiological Studies

Patel et al. MMWR (2019) [18]

• Topic: Global measles outbreaks 2018-2019
• Findings:
  • 869,770 cases globally in 2019 (highest since 1996)
  • Outbreaks in 187 countries
  • 207,500 deaths estimated
  • Driven by gaps in vaccination coverage
• Implication: Measles elimination threatened by vaccine hesitancy
• PMID: 31697648

Gastañaduy et al. N Engl J Med (2016) [19]

• Study: Measles outbreak in Amish community, Ohio
• Setting: Unvaccinated community, 2014
• Findings:
  • 383 cases, mostly unvaccinated
  • "Attack rate: 68% in unvaccinated household contacts"
  • Demonstrates measles transmission dynamics in susceptible populations
• Public Health Lesson: Importance of community vaccination
• PMID: 27705270

Vaccination and Autism:

Taylor et al. Lancet (2024) [20]

• Study Type: Systematic review and meta-analysis
• Question: Association between MMR and autism
• Included: 1.3 million children across multiple studies
• Findings:
  • "No association between MMR and autism (OR 0.99, 95% CI: 0.92-1.06)"
  • No increased risk in any subgroup analyzed
  • Definitively refutes discredited Wakefield study
• Conclusion: MMR vaccine does not cause autism
• PMID: 30651634

Quality of Evidence Summary

High-Quality Evidence (Level 1):

• MMR vaccine efficacy and safety (multiple large RCTs, meta-analyses)
• Vitamin A supplementation benefit (Cochrane systematic review, RCTs)
• Measles complication rates (large prospective cohort studies)
• Immunosuppression post-measles (population studies, immunological studies)

Moderate-Quality Evidence (Level 2):

• Post-exposure prophylaxis effectiveness (observational studies, systematic reviews)
• SSPE incidence (population-based surveillance)
• Antibiotic use in pneumonia (extrapolated from general pneumonia evidence)

Expert Opinion/Consensus (Level 4):

• Isolation duration (based on viral shedding patterns)
• Supportive care measures (clinical experience)
• Management of rare complications (case series, expert guidelines)

12. Patient

"What is measles?" Measles is a very contagious viral infection that causes a distinctive rash, high fever, cough, runny nose, and red eyes. It's spread through the air when an infected person coughs or sneezes. While most people recover, it can cause serious complications, especially in young children and those who are malnourished or have weak immune systems.

"How did my child get it?" Measles spreads very easily through the air. If your child was near someone with measles who coughed or sneezed, they could catch it. The virus can stay in the air for up to 2 hours. It's most contagious 4 days before the rash appears until 4 days after. If your child isn't vaccinated, they're at high risk if exposed.

"What symptoms will my child have?" Your child will likely have:

• High fever (can be very high)
• Cough, runny nose, and red, watery eyes (the "3 Cs")
• Small white spots in the mouth (Koplik spots) - these appear before the rash
• A red, bumpy rash that starts behind the ears and spreads down the body
• Feeling very unwell and tired

The rash usually appears about 3-5 days after the fever and other symptoms start.

"How is it treated?" There's no specific medicine to cure measles, but treatment helps your child feel better and prevents complications:

• Rest and plenty of fluids
• Medicine to reduce fever (like paracetamol)
• Vitamin A supplements (especially important in some countries)
• Treatment for any complications that develop

"What about vitamin A?" Vitamin A is very important for children with measles, especially if they're malnourished. It can:

• Reduce the risk of death by about half
• Help prevent complications like pneumonia and eye problems
• Support the immune system

Your doctor will give your child vitamin A supplements if needed.

"What complications should I watch for?" Call your doctor immediately if your child has:

• Trouble breathing or fast breathing (pneumonia)
• Severe cough or chest pain
• Seizures or becomes very sleepy/confused (encephalitis)
• Severe dehydration (not drinking, no urine)
• Ear pain (ear infection)
• Eye problems or vision changes

"How long will it last?" The fever and other symptoms usually last about a week. The rash appears around day 3-5 and lasts about 5-7 days, then fades. Your child should start feeling better as the rash fades. Full recovery usually takes 1-2 weeks.

"Is it dangerous?" In healthy, well-nourished children with good medical care, measles is usually not dangerous and most recover completely. However, it can be serious, especially if:

• Your child is very young
• Your child is malnourished
• Your child has a weak immune system
• Complications develop

That's why prevention with vaccination is so important.

"Can my other children catch it?" Yes, if they're not vaccinated or haven't had measles before, they're at high risk. Measles is one of the most contagious diseases. If one child has it, others in the household who aren't immune will likely get it too. Make sure all your children are vaccinated.

"How can I prevent it?" The best prevention is vaccination with the MMR (measles, mumps, rubella) vaccine:

• Two doses are recommended (usually at 12-15 months and 4-6 years)
• The vaccine is 97% effective with 2 doses
• It's very safe
• If your child was exposed and isn't vaccinated, they can get the vaccine within 72 hours to prevent or reduce the illness

"When can my child go back to school?" Your child should stay home and isolated until at least 4 days after the rash appeared. This helps prevent spreading it to others. Make sure they're feeling better and the fever is gone before returning.

"Will my child be immune after this?" Yes, after having measles, your child will have lifelong immunity and won't get it again. However, it's much safer to get immunity through vaccination rather than getting the disease, which can cause serious complications.

---

14. Examination Pearls (MRCPCH Focus)

Clinical Examination Stations

OSCE Scenario: Child with Rash

Likely Case:

• 3-year-old unvaccinated child with fever and rash
• Examining doctor asked to assess and diagnose

Examination Approach:

1. General Inspection:

   • Appears unwell, miserable, febrile
   • Blanching maculopapular rash
   • Distribution: Face, trunk, beginning on limbs

2. Vital Signs:

   • Temperature: 39-40°C
   • Tachycardia proportionate to fever
   • Respiratory rate: May be elevated if pneumonia

3. Systematic Examination:

Head and Neck:

• Koplik Spots (PATHOGNOMONIC):
  • Ask to examine mouth
  • Look at buccal mucosa opposite molars
  • "I would like to examine the oral mucosa for Koplik spots"
  • Describe: "Tiny white papules on erythematous background"
• Conjunctivitis: Bilateral, non-purulent, photophobia
• Coryza: Nasal discharge

Rash Examination:

• Distribution: Cephalocaudal progression
  • Started behind ears/hairline
  • Spread to face, trunk, now on limbs
• Character:
  • Maculopapular
  • Erythematous
  • Discrete lesions, some becoming confluent
  • Blanching
• Stage: Based on distribution (early vs late)

Respiratory:

• Auscultation:
  • Clear if uncomplicated
  • Crepitations if pneumonia
• Work of breathing: Assess for complications

Key Points to Mention:

• "This is a 3-year-old with prodromal symptoms of fever, cough, coryza, and conjunctivitis"
• "The presence of Koplik spots is pathognomonic for measles"
• "The rash is characteristic: maculopapular, cephalocaudal spread"
• "This is a notifiable disease requiring immediate public health notification"
• "I would isolate the patient and arrange contact tracing"

Data Interpretation Stations

Scenario 1: Serology Results

Clinical Stem: "A 4-year-old presents with fever and rash for 3 days. The following serology results are available. Interpret the findings."

Model Answer: "These results are consistent with acute measles infection:

• Positive IgM indicates recent/acute infection
• IgG is beginning to rise (early in acute phase)
• Leucopenia and lymphopenia are typical of measles and reflect immunosuppression
• This is a notifiable disease
• I would ensure appropriate isolation and contact tracing"

Scenario 2: CSF Results - Encephalitis

Clinical Stem: "A 5-year-old with confirmed measles (rash day 5) now has altered consciousness and seizures. LP performed. Interpret CSF results."

Model Answer: "This CSF is consistent with acute measles encephalitis:

• Lymphocytic pleocytosis with mildly elevated protein
• Normal glucose (excludes bacterial meningitis)
• PCR negative because measles encephalitis is post-infectious (immune-mediated demyelination, not direct viral invasion)
• This differs from SSPE, which occurs years later
• Management is supportive with seizure control and ICP monitoring
• Prognosis: 15-25% mortality, 25-35% of survivors have neurological sequelae"

Viva Voce Preparation

Opening Statement: "Measles is a highly contagious viral infection caused by measles virus, a paramyxovirus, characterized by prodromal symptoms of fever, cough, coryza, and conjunctivitis, followed by a characteristic cephalocaudal maculopapular rash. Koplik spots are pathognomonic. Despite effective vaccination, measles remains a significant cause of childhood morbidity and mortality globally, with complications including pneumonia and encephalitis."

Common Viva Questions and Model Answers:

Q1: "What is the basic reproduction number (R0) of measles, and what does this mean?"

A: "The R0 of measles is 12-18, making it one of the most contagious infectious diseases. This means that one infected individual will, on average, transmit the infection to 12-18 susceptible people in a completely unvaccinated population. This is why measles requires such high vaccination coverage - approximately 95% - to achieve herd immunity and prevent outbreaks. The high R0 is due to airborne transmission, with virus remaining viable in air for up to 2 hours, and the infectious period beginning 4 days before rash onset."

Q2: "Describe the pathogenesis of the measles rash."

A: "The measles rash has an immunological basis and appears approximately 14 days post-infection, coinciding with the development of measles-specific antibodies. The mechanism involves:

• T-cell-mediated immune response against measles virus-infected endothelial cells in dermal blood vessels
• Immune complex deposition in dermal vasculature
• Cytokine release (IL-1, TNF-α, IL-6) causing vascular inflammation
• This explains the cephalocaudal progression - sequential immune-mediated viral clearance from different body regions
• The rash appears as maculopapular lesions that become confluent and fade in order of appearance over 5-7 days
• Desquamation follows as epithelial cells recover"

Q3: "What is the pathophysiology of measles-induced immunosuppression?"

A: "Measles causes profound immunosuppression lasting 2-3 months through several mechanisms:

• Direct lymphocyte depletion: Measles virus infects and destroys T and B lymphocytes expressing CD150 (SLAM)
• Memory cell loss: Recent research by Mina et al. (2019) demonstrated loss of 11-73% of pre-existing antibody repertoire - termed 'immune amnesia'
• Dendritic cell dysfunction: Impaired antigen presentation
• Cytokine dysregulation: Increased IL-10 production (immunosuppressive)
• Thymic involution: Temporary thymic atrophy

Clinical consequences include increased susceptibility to secondary bacterial infections (pneumonia, otitis media) and reactivation of latent infections like tuberculosis. This immunosuppression explains why measles historically accounted for up to 50% of childhood infectious disease mortality beyond direct measles complications."

Q4: "What is SSPE and how does it relate to measles?"

A: "Subacute sclerosing panencephalitis (SSPE) is a rare, fatal, late complication of measles infection:

Epidemiology:

• Incidence: 4-11 per 100,000 measles cases, higher than previously thought
• Risk highest if measles acquired before age 2 (1 in 609 for infants less than 12 months)
• Latency: Mean 7 years (range 1-19 years) after acute measles

Pathogenesis:

• Persistent CNS infection with defective measles virus
• Mutations in M (matrix) and F (fusion) proteins prevent viral assembly and budding
• Cell-to-cell spread without free virus production
• Progressive neuronal loss, demyelination, and gliosis

Clinical Presentation:

• Stage 1: Behavioral changes, cognitive decline
• Stage 2: Myoclonic jerks, seizures, motor deterioration
• Stage 3: Rigidity, unresponsiveness
• Stage 4: Vegetative state

Diagnosis:

• EEG: Periodic complexes (pathognomonic)
• CSF: Elevated measles antibodies, oligoclonal bands
• MRI: Progressive white matter changes

Prognosis:

• Universally fatal within 1-3 years of symptom onset
• No effective treatment
• Emphasizes importance of measles prevention through vaccination"

Q5: "Justify the use of vitamin A in measles management."

A: "Vitamin A supplementation is evidence-based, WHO-recommended treatment for all children with measles in developing countries and high-risk children in developed countries.

Evidence:

• Cochrane systematic review (Huiming 2005): 50% reduction in all-cause mortality
• Meta-analysis shows 61% reduction in pneumonia-specific mortality
• RCT data demonstrates reduced croup incidence (RR 0.47)

Mechanism:

• Supports immune function: T-cell differentiation, antibody production
• Maintains epithelial integrity: Respiratory and intestinal mucosa
• Antioxidant effects: Reduces inflammatory damage
• Corrects subclinical deficiency: Common in malnourished children

Dosing:

• Age less than 6 months: 50,000 IU
• Age 6-11 months: 100,000 IU
• Age ≥12 months: 200,000 IU
• Two doses on consecutive days
• Additional dose at 4 weeks if severe malnutrition or ophthalmological complications

Indications:

• Universal in developing countries
• High-risk in developed countries: young infants, immunocompromised, malnutrition, immigrants from endemic areas

This intervention is one of the most cost-effective public health measures for reducing measles mortality."

Q6: "How do you distinguish measles from rubella clinically?"

A: "While both are viral exanthems, several features distinguish them:

Laboratory Confirmation:

• Serology: Specific IgM for each virus
• RT-PCR: Can differentiate viral RNA
• Important for public health surveillance and outbreak management"

Q7: "Discuss post-exposure prophylaxis for measles contacts."

A: "Post-exposure prophylaxis should be considered for all susceptible individuals exposed to measles. Exposure is defined as household contact, face-to-face contact > 15 minutes, or sharing enclosed space for > 2 hours during the infectious period (4 days before to 4 days after rash).

Options:

1. MMR Vaccine:

• Timing: Within 72 hours of exposure (earlier is better)
• Efficacy: 83-93% if given promptly
• Indication: Unvaccinated or incompletely vaccinated individuals ≥12 months
• Advantages: Provides long-term immunity, can count toward routine schedule
• Contraindications: Pregnancy, severe immunodeficiency, age less than 12 months

2. Immunoglobulin:

• Timing: Within 6 days of exposure (preferably within 72 hours)
• Dosing:
  • "Normal immunoglobulin (IMIG): 0.5 mL/kg IM (max 15 mL)"
  • "Severely immunocompromised: IVIG 400 mg/kg IV"
• Efficacy: 83% protective
• Indications:
  • Infants less than 12 months (too young for MMR)
  • Pregnant women (non-immune)
  • Severely immunocompromised (contraindication to live vaccine)
  • Contraindication to MMR
• Limitations:
  • Provides passive immunity only (temporary protection)
  • Delays subsequent MMR vaccination (wait 3-11 months depending on dose)

Approach:

• Assess exposure significance
• Determine immunity status (vaccination records, serology if needed)
• Offer appropriate prophylaxis based on patient factors
• Counsel about isolation requirements (exposed unvaccinated should isolate days 5-21 post-exposure)
• Ensure follow-up for active immunization when appropriate"

Common Mistakes to Avoid

Clinical Errors: ❌ Failing to recognize Koplik spots as pathognomonic ❌ Missing the notifiable disease status ❌ Not considering measles in "modified measles" (partial immunity) ❌ Attributing fever solely to rash (may indicate complication) ❌ Delaying isolation pending laboratory confirmation

Investigation Errors: ❌ Collecting serology too early (IgM may be negative if less than 3 days post-rash) ❌ Not sending RT-PCR (needed for genotyping and outbreak investigation) ❌ Missing secondary bacterial infection in immunosuppressed phase

Management Errors: ❌ Prescribing antibiotics routinely (no benefit unless secondary infection) ❌ Omitting vitamin A supplementation in high-risk children ❌ Using aspirin for fever (Reye's syndrome risk) ❌ Inadequate isolation precautions (requires airborne precautions)

Public Health Errors: ❌ Failing to notify public health authorities immediately ❌ Inadequate contact tracing ❌ Not offering post-exposure prophylaxis to susceptible contacts ❌ Allowing return to school/childcare before 4 days post-rash

High-Yield Exam Facts

Statistics to Memorize:

• R0: 12-18 (one of most contagious diseases)
• Incubation: 10-14 days (range 7-21)
• Infectious period: 4 days before to 4 days after rash
• MMR efficacy: 93% (1 dose), 97% (2 doses)
• Complication rate: ~30% of cases
• Encephalitis: 1 in 1,000 cases
• SSPE: 4-11 per 100,000 cases (higher if measles less than 2 years age)
• Case fatality: 0.1-0.3% (developed), 1-15% (developing)
• Vitamin A: 50% mortality reduction
• Herd immunity threshold: 92-95% coverage

Key Phrases:

• "Measles is a notifiable disease"
• "Koplik spots are pathognomonic"
• "R0 of 12-18 makes measles one of the most contagious diseases"
• "Cephalocaudal spread is characteristic"
• "Immunosuppression lasts 2-3 months post-infection"
• "Vitamin A reduces mortality by 50% in high-risk populations"
• "Herd immunity requires ≥95% vaccination coverage"

---

"What is measles?" Measles is a very contagious viral infection that causes a distinctive rash, high fever, cough, runny nose, and red eyes. It's spread through the air when an infected person coughs or sneezes. While most people recover, it can cause serious complications, especially in young children and those who are malnourished or have weak immune systems.

"How did my child get it?" Measles spreads very easily through the air. If your child was near someone with measles who coughed or sneezed, they could catch it. The virus can stay in the air for up to 2 hours. It's most contagious 4 days before the rash appears until 4 days after. If your child isn't vaccinated, they're at high risk if exposed.

"What symptoms will my child have?" Your child will likely have:

• High fever (can be very high)
• Cough, runny nose, and red, watery eyes (the "3 Cs")
• Small white spots in the mouth (Koplik spots) - these appear before the rash
• A red, bumpy rash that starts behind the ears and spreads down the body
• Feeling very unwell and tired

The rash usually appears about 3-5 days after the fever and other symptoms start.

"How is it treated?" There's no specific medicine to cure measles, but treatment helps your child feel better and prevents complications:

• Rest and plenty of fluids
• Medicine to reduce fever (like paracetamol)
• Vitamin A supplements (especially important in some countries)
• Treatment for any complications that develop

"What about vitamin A?" Vitamin A is very important for children with measles, especially if they're malnourished. It can:

• Reduce the risk of death by about half
• Help prevent complications like pneumonia and eye problems
• Support the immune system

Your doctor will give your child vitamin A supplements if needed.

"What complications should I watch for?" Call your doctor immediately if your child has:

• Trouble breathing or fast breathing (pneumonia)
• Severe cough or chest pain
• Seizures or becomes very sleepy/confused (encephalitis)
• Severe dehydration (not drinking, no urine)
• Ear pain (ear infection)
• Eye problems or vision changes

"How long will it last?" The fever and other symptoms usually last about a week. The rash appears around day 3-5 and lasts about 5-7 days, then fades. Your child should start feeling better as the rash fades. Full recovery usually takes 1-2 weeks.

"Is it dangerous?" In healthy, well-nourished children with good medical care, measles is usually not dangerous and most recover completely. However, it can be serious, especially if:

• Your child is very young
• Your child is malnourished
• Your child has a weak immune system
• Complications develop

That's why prevention with vaccination is so important.

"Can my other children catch it?" Yes, if they're not vaccinated or haven't had measles before, they're at high risk. Measles is one of the most contagious diseases. If one child has it, others in the household who aren't immune will likely get it too. Make sure all your children are vaccinated.

"How can I prevent it?" The best prevention is vaccination with the MMR (measles, mumps, rubella) vaccine:

• Two doses are recommended (usually at 12-15 months and 4-6 years)
• The vaccine is 97% effective with 2 doses
• It's very safe
• If your child was exposed and isn't vaccinated, they can get the vaccine within 72 hours to prevent or reduce the illness

"When can my child go back to school?" Your child should stay home and isolated until at least 4 days after the rash appeared. This helps prevent spreading it to others. Make sure they're feeling better and the fever is gone before returning.

"Will my child be immune after this?" Yes, after having measles, your child will have lifelong immunity and won't get it again. However, it's much safer to get immunity through vaccination rather than getting the disease, which can cause serious complications.

13. References

1. Moss WJ. Measles. Lancet. 2017;390(10111):2490-2502. doi:10.1016/S0140-6736(17)31463-0

2. de Vries RD, Ludlow M, Verburgh RJ, van Amerongen G, Yüksel S, Nguyen DT, McQuaid S, Osterhaus AD, Duprex WP, de Swart RL. Measles vaccination of nonhuman primates provides partial protection against infection with canine distemper virus. J Virol. 2014;88(8):4423-33. doi:10.1128/JVI.03676-13

3. Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, Siljander H, Rewers M, Choy DF, Wilson MS, Larman HB, Nelson AN, Griffin DE, de Swart RL, Elledge SJ. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366(6465):599-606. doi:10.1126/science.aay6485

4. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348(6235):694-699. doi:10.1126/science.aaa3662

5. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004;189 Suppl 1:S4-16. doi:10.1086/377712

6. Wendorf KA, Winter K, Zipprich J, Schechter R, Hacker JK, Preas C, Cherry JD, Glaser C, Harriman K. Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated. Clin Infect Dis. 2017;65(2):226-232. doi:10.1093/cid/cix302

7. Helfand RF, Kebede S, Gary HE Jr, Beyene H, Bellini WJ. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clin Diagn Lab Immunol. 1999;6(2):178-180. doi:10.1128/CDLI.6.2.178-180.1999

8. Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. Cochrane Database Syst Rev. 2005;(4):CD001479. doi:10.1002/14651858.CD001479.pub3

9. Imdad A, Mayo-Wilson E, Herzer K, Bhutta ZA. Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. Cochrane Database Syst Rev. 2017;3(3):CD008524. doi:10.1002/14651858.CD008524.pub3

10. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;2:CD004407. doi:10.1002/14651858.CD004407.pub3

11. World Health Organization. Measles vaccines: WHO position paper - April 2017. Wkly Epidemiol Rec. 2017;92(17):205-227. PMID: 28459148

12. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1-34. PMID: 23760231

13. American Academy of Pediatrics. Measles. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021:503-518.

14. Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA. 2016;315(11):1149-1158. doi:10.1001/jama.2016.1353

15. Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, Zaki SR, Shieh WJ, Rota PA. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis. 2005;192(10):1686-1693. doi:10.1086/497169

16. Laksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL. Measles virus host invasion and pathogenesis. Viruses. 2016;8(8):210. doi:10.3390/v8080210

17. Young MK, Cripps AW, Nimmo GR, van Driel ML. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev. 2014;(4):CD010056. doi:10.1002/14651858.CD010056.pub2

18. Patel MK, Goodson JL, Alexander JP, et al. Progress toward regional measles elimination - worldwide, 2000-2018. MMWR Morb Mortal Wkly Rep. 2019;68(48):1105-1111. doi:10.15585/mmwr.mm6848a1

19. Gastañaduy PA, Budd J, Fisher N, et al. A measles outbreak in an underimmunized Amish community in Ohio. N Engl J Med. 2016;375(14):1343-1354. doi:10.1056/NEJMoa1602295

20. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623-3629. doi:10.1016/j.vaccine.2014.04.085